Acadia Pharmaceuticals | ACAD - Trade Debtors


Acadia Pharmaceuticals reported $148.38M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 148.38M 153K Mar/2026
ALKERMES USD 407.63M 73.6M Mar/2026
Alnylam Pharmaceuticals USD 883.96M 106.39M Mar/2026
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Cara Therapeutics USD 2.24M 2.26M Mar/2025
Corcept Therapeutics USD 39.07M 20.71M Mar/2026
Cytokinetics USD 6.83M 10.94M Mar/2026
Eisai JPY 227B 22.05B Mar/2026
Eli Lilly USD 21.18B 1.02B Mar/2026
Incyte USD 1.05B 27.09M Mar/2026
J&J USD 21.33B 3.72B Dec/2025
Moderna USD 71M 113M Mar/2026
Neurocrine Biosciences USD 768.1M 81.3M Mar/2026
Pfizer USD 16.17B 332M Mar/2026
Prothena USD 5.16M 0 Dec/2023
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024
Vertex Pharmaceuticals USD 2B 56.7M Mar/2026